Viatris, a global healthcare company, completed the acquisition of Oyster Point Pharma, an American biopharmaceutical firm, and Famy Life Sciences, a drug development platform, for $750m. "We've been talking about the potential power of our Global Healthcare Gateway since we launched Viatris, that is why I am especially excited that the two ophthalmology acquisitions we announced today came about directly as the result of the Global Healthcare Gateway. These acquisitions bring us an innovative growth asset, Tyrvaya®, and five additional Phase III or Phase III-ready programs that give us a significant head-start in creating a leading ophthalmology franchise," Michael Goettler, Viatris CEO.